January 28, 2015     Japanese 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
Dainippon Sumitomo, AstraZeneca to Develop Antiallergic Drug

 Antiallergic Drug
Osaka, May 8, 2008 (Jiji Press) - Dainippon Sumitomo Pharma Co. <4506> said Thursday it will start clinical development of a therapeutic agent for allergic disorders in collaboration with AstraZeneca PLC.

Through joint researches since 2004, the Japanese and British companies have discovered a chemical compound which can act as an immune response modifier that is effective against bronchial asthma and allergic rhinitis.

If the drug is successfully developed, Dainippon Sumitomo will sell the product in Japan, China, South Korea and Taiwan, while AstraZeneca will cover the rest of the world.

Dainippon Sumitomo will receive royalties for sales in the United States and some European countries.

The market for bronchial asthma drugs is estimated at 200 billion yen for Japan and 2 trillion yen for the world. The market for allergic rhinitis drugs is seen at 100 billion yen for Japan and 1.6 trillion yen for the world.

By Jiji Press, (c) Jiji Press

Copyright © 2015 JCN. All rights reserved. A division of Japan Corporate News Network KK.

 Company Profile |   Print  |   Alerts
ACN Newswire

 Recent  Dainippon Sumitomo News  
  Dainippon Sumitomo Pharma Establishes Anti-Cancer Drugs Sales Company in the U.S.  (Oct 10, 2013)
  Dainippon Sumitomo Pharma Opens Subsidiary in Singapore  (Jan 22, 2013)
  Kobe University, KNC Labs and Dainippon Sumitomo to Research Anti-cancer Agent  (Dec 28, 2012)
  NOTICE of establishment of Drug Discovery Consortium in neuropsychiatric area  (Oct 23, 2008)
  Dainippon Sumitomo, AstraZeneca to Develop Antiallergic Drug  (May 8, 2008)
  Dainippon Sumitomo Pharma Review of Overseas Development of Lurasidone (SM-13496), an Atypical Antipsychotic  (Dec 13, 2006)
  Dainippon Sumitomo Pharma Revises Domestic Development Plan of AC-5216, an Antianxiety/antidepressant Agent  (Nov 28, 2006)
  Dainippon Sumitomo Pharma 2006 Annual Report to Shareholders, 'True Quality, Our New Beginning'  (Sept 21, 2006)
  Dainippon Sumitomo Pharma 2006 Annual Report to Shareholders, 'True Quality, Our New Beginning'  (Sept 21, 2006)
  Dainippon Sumitomo Pharma Enters into Partnership Agreement on Anti-Hypertension and Hepatocellular Cancer Drugs  (July 26, 2006)

 Recent  Drugs & OTC News   
Otsuka Announces Termination of Contracts (Jan 8, 2015)
Otsuka: U.S. FDA Approves Labeling Update of Abilify Maintena (Aripiprazole) (Dec 8, 2014)
Otsuka Pharmaceutical to Launch L-Cartin FF Tablets for Carnitine Deficiencies in Japan (Dec 1, 2014)
Otsuka Group Establishes New Company; Strengthens Presence in Vending Machine Market (Nov 17, 2014)
Otsuka's 'QuickNavi-Flu' Diagnostic Kit to Provide Additional Diagnosis-Related Information (Oct 14, 2014)
Nitto Denko Anti-fibrosis Drug Starts Phase-1b Dosing for Cirrhosis Patients in the US (Oct 10, 2014)
Mitsui to Participate in KIFMEC Specific Purpose Company (Aug 18, 2014)
Yokogawa Technology Selected for JSTA's Next-generation Technology Transfer Program (Aug 8, 2014)
Sysmex, Toppan Printing to Collaborate in Genetic Analysis Testing (June 9, 2014)
Takara Bio Submits IND Application to FDA for HF10 Anti-cancer Therapy (May 12, 2014)

More Drugs & OTC news...
CSR Report Download
Annual Reports

  More >>    
Most Popular

About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)